Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Yoshida, K. Articles by Shimizu, T. Search for Related Content PubMed Citation Articles by Yoshida, K. Articles by Shimizu, T. Depression

Favorable Effect of Milnacipran on Depression Induced by Interferon-Alpha

SIR: Milnacipran is a novel serotonin and noradrenaline reuptake inhibitor. To our knowledge, this is the first report of a patient whose depressive symptoms induced by interferon ameliorated by treatment with milnacipran.

Case Report
A 71-year-old man with no history and no family history of psychiatric disorders was admitted to our hospital for renal cancer. He underwent surgery for removal of his left kidney and of a metastatic focus in a lumbar spinal process. One month after the operation, intramuscular injections of interferon--2a were started at a dosage of 3 million units three times weekly. One week after the start of interferon therapy, he started to complain of depressive mood, lassitude, and irritability. The dosage of interferon was reduced to 3 million units once a week, and trazodone 100 mg/day was prescribed. Four weeks after beginning the trazodone, the patient's irritability remitted and his depressive mood lessened. His lassitude remained unchanged.

The patient's depressive mood increased during the 2 or 3 days following the interferon injections, and he requested another reduction in the dosage of interferon. It was reduced to 3 million units once monthly, but the patient's depressive mood remained, and it increased during the 2 or 3 days following the injection. We suggested an increase in the dosage of trazodone, but the patient refused because of the side effect of thirst. We suggested trying a different antidepressant, namely, milnacipran, and the patient agreed. The trazodone dosage was reduced to 50 mg/day, and milnacipran 50 mg/day was started. Two weeks later, the trazodone was stopped and the milnacipran dosage was increased to 75 mg/day. One week after the start of the new prescription, the patient's thirst lessened. Four weeks afterward, his depressive mood and lassitude disappeared completely. His mood did not deteriorate during the 2 or 3 days following interferon injections. More than 1 year has passed since his operation. His cancer and depressive symptoms have not returned.

Comment
Interferons have both antiviral and antineoplastic properties that allow them to be used to treat a variety of medical conditions.¹ Symptoms of depression are frequently seen in patients receiving treatment with interferon-,² and treatment of the depression is a matter of concern in clinical practice. Kamata et al.³ examined the effect of a single intracerebroventricular injection of interferon- on monoamine concentrations in the rat brain. They found that the levels of serotonin and noradrenaline were reduced in a dose-dependent manner in the frontal cortex. These neurochemical changes are possible mechanisms of depression induced by interferon. In our patient, trazodone 100 mg/day was partially effective, and milnacipran 75 mg/day was completely effective. The primary pharmacological action of trazodone is a blockade of 5-HT₂ postsynaptic receptors.⁴ The primary pharmacological action of milnacipran is a dual reuptake-inhibition of serotonin and noradrenaline.⁵ Given the neurochemical changes reported by Kamata et al.,³ an antidepressant that activates both serotonin and noradrenaline neurotransmission may be more effective for depression induced by interferon-.

REFERENCES

1. Trask PC, Esper P, Riba M, et al: Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18:2316-2326[Abstract/Free Full Text]
2. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876[Abstract/Free Full Text]
3. Kamata M, Higuchi H, Yoshimoto M, et al: Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000; 10:129-132[Medline]
4. Feighner JP: Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60(suppl 4):4-11; discussion 12-13
5. Spencer CM, Wilde MI: Milnacipran: a review of its use in depression. Drugs 1998; 56:405-427[Medline]

This article has been cited by other articles:

				P. Malek-Ahmadi and F. Prabhu Venlafaxine for Treatment of Interferon Alfa-Induced Depression Ann. Pharmacother., November 1, 2006; 40(11): 2075 - 2075. [Full Text] [PDF]

Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Yoshida, K. Articles by Shimizu, T. Search for Related Content PubMed Citation Articles by Yoshida, K. Articles by Shimizu, T. Depression

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us